Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMMUNOPRESERVE: Durvalumab + Tremelimumab + RT in MIBC
NCT03702179Phase 2Completed
- Sponsor
- SOGUG
- Start
- Nov 2018
- Primary completion
- Sep 2020
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of durvalumab, tremelimumab in muscle-invasive bladder cancer (MIBC), sponsored by SOGUG. Started Nov 2018; status: completed.
02
Drugs
durvalumabtremelimumab
03
Conditions
muscle-invasive bladder cancer (MIBC)
Beyond the preview
Go deeper on NCT03702179.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03702179.